乐观
$10.69
情景价格
$9.590
+0.353 (+3.68%)收盘时
Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation.
Orthofix Medical Inc is currently priced at $9.17, which is significantly below the average analyst price target of $13. However, the stock has a negative RSI of 46.37, indicating a potential lack of momentum. The company has also reported a 38.21% year-to-date decline, raising concerns about its long-term viability. While there are positive signs such as a recent revenue beat and an increase in adjusted EBITDA guidance, the ongoing investigation into fiduciary breaches poses a significant risk. Therefore, it may be prudent to hold off on buying until there is more clarity on these issues.
Canaccord
$13
2026-08-10
Canaccord
2026-08-10
目标价
$13
Barrington
$14
2026-08-06
Barrington
2026-08-06
目标价
$14
Stifel
$13
2026-08-05
Stifel
2026-08-05
目标价
$13
Stifel
$18
2026-03-09
Stifel
2026-03-09
目标价
$18
Canaccord
$20
2026-02-26
Canaccord
2026-02-26
目标价
$20
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Halper Sadeh LLC Investigates Orthofix Management for Breach of Duties

Orthofix Medical Inc. Under Investigation for Fiduciary Breaches

Orthofix Medical Q2 2026 Earnings Call Insights

Orthofix Medical Reports Q2 Earnings Beat but Shares Drop

Orthofix Medical Inc. Q2 Earnings Beat Expectations
Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Orthofix Medical Inc is currently priced at $9.17, which is significantly below the average analyst price target of $13. However, the stock has a negative RSI of 46.37, indicating a potential lack of momentum. The company has also reported a 38.21% year-to-date decline, raising concerns about its long-term viability. While there are positive signs such as a recent revenue beat and an increase in adjusted EBITDA guidance, the ongoing investigation into fiduciary breaches poses a significant risk. Therefore, it may be prudent to hold off on buying until there is more clarity on these issues.
7 analysts cover OFIX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 21.33.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。